Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040

About this update from Anixa Biosciences, Inc.

Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in South Korea through 2040, expanding the Company's growing global IP estateExpands global intellectual property coverage in markets with increasing breast cancer incidence rates and greater concentrations of younger breast cancer patientsSAN JOSE, Calif., June 29, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Korean Ministry of Intellectual Property (MOIP) has issued Patent Number 10-2960889 related to Anixa's breast cancer vaccine technology. This composition-of-matter patent, exclusively licensed from Cleveland Clinic, protects the Company's novel approach to breast cancer prevention and treatment in South Korea through 2040, addressing a disease for which no preventive vaccine is currently approved anywhere in the world.With this issued patent, Anixa continues to expand the international scope of its intellectual property portfolio, reinforcing its leadership in the field of cancer immunotherapy. The Korean patent complements Anixa's existing patent portfolio in the United States and other key international markets, further strengthening the Company's global intellectual property estate. The expanded patent protection enhances Anixa's ability to pursue future regulatory approvals, strategic partnerships and commercialization opportunities."Each global patent we secure deepens the global foundation we are building for our breast cancer vaccine," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "As we continue clinical development in the U.S., our growing international patent estate further strengthens our ability to pursue global opportunities and potentially partner with larger pharmaceutical companies for worldwide commercialization. In our recently completed Phase 1 clinical trial conducted at Cleveland Clinic, the vaccine met all major primary endpoints, was safe and well tolerated, and generated immune responses in 74% of participants, supporting continued clinical development of this novel preventive approach."Breast cancer remains the most commonly diagnosed cancer among women worldwide, and currently there is no approved vaccine to prevent it. While breast cancer survival rates are high in S...

View stock analysis, news, and events for Anixa Biosciences, Inc.